South Korea Bans Syringe Hoarding as Middle East Conflict Disrupts Naphtha Supply

South Korea's health authorities activated a nationwide ban on the hoarding of medical syringes and needles starting 14 April 2026, as the prolonged Middle East conflict continues to strain raw material supplies feeding the country's medical device industry. The Ministry of Food and Drug Safety published the notice on 13 April 2026, with enforcement running through 30 June 2026 and a possible extension depending on market conditions.

The core problem traces back to naphtha, a petroleum-derived feedstock used to produce the synthetic resins required for disposable syringes, surgical gloves, intravenous fluid containers, and a wide range of single-use medical consumables. With crude oil flows from the Middle East disrupted by the ongoing conflict, naphtha availability has tightened, driving up production costs and fueling anxiety across hospitals, clinics, and pharmacies.

Daily syringe output in South Korea remained around 4.5 million units, slightly above 2025 averages, yet front-line facilities reported dwindling stocks. Online distribution platforms saw rising prices and emptied listings, signs pointing to stockpiling behavior rather than a manufacturing collapse. Earlier in April 2026, Korea Vaccine notified medical institutions of price hikes ranging from 15 to 20 percent on all disposable syringe and needle products, with the increase set to run for two months. Korea Vaccine, Shinchang Medical, and Becton Dickinson Korea together control roughly 80 percent of the domestic syringe market.

Under the new rule, manufacturers and sellers are prohibited from holding inventories greater than 150 percent of their 2025 monthly average sales volume for more than five consecutive days. Refusing sales without justifiable grounds, concentrating supply toward specific buyers, and any conduct that distorts distribution are also banned. Violators face up to three years in prison or fines reaching 100 million won, around 70,000 US dollars.

On 15 April 2026, Prime Minister Kim Min-seok instructed ministries to enforce the rules strictly during an emergency economic headquarters meeting, citing the fragile state of the ceasefire between the United States and Iran. The prime minister urged relevant ministries to clamp down firmly on behavior disrupting market order.

Beyond syringes, the Korean government placed six categories of medical products under intensive daily monitoring: intravenous solution packaging materials, IV sets, eye drop containers, syringes, needles, and hemodialysis solution containers. Sterile packaging, drug paper, medicine containers, and medical waste bins were added to a secondary watch list managed by the Ministry of Health and Welfare. A dedicated reporting center operated by the Health Insurance Review and Assessment Service (HIRA) was launched to collect tips on hoarding and price-fixing.

The intervention forms part of a broader emergency response framework that began in March 2026 with hoarding bans on petroleum products, followed by urea and urea solution, and now petrochemical feedstocks including ethylene, propylene, and butadiene. The Ministry of Food and Drug Safety asked the Ministry of Trade, Industry and Energy to prioritize naphtha allocation for essential healthcare production, while expedited procedures for changing raw materials used in medicine packaging are under review.

Hospitals face particular pressure because Korea's national health insurance system bundles most medical consumables into per-procedure reimbursement fees, classifying them as non-separately billable. Healthcare providers must absorb cost increases without passing them on to patients, squeezing margins at a time when supply uncertainty is already straining operations. Twelve health and pharmaceutical associations, including the Korean Medical Association, the Korean Hospital Association, and the Korean Pharmaceutical Association, signed a cooperation declaration to coordinate response efforts and help stabilize the supply chain.

Government officials stated the measures aim to prevent patient harm by blocking panic buying and distribution distortions affecting essential medical supplies, and will be reassessed continuously until market conditions normalize.